The BCR-ABL story: Bench to bedside and back

Annual Review of Immunology

Volumn 22, Issue , 2004, Pages 247-306

  Wong, Stephane ^a   Witte, Owen N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Imatinib mesylate; Inhibitor mechanism; Leukemia; Signal transduction; Tyrosine kinase

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ADAPHOSTIN; ALPHA INTERFERON; ARSENIC TRIOXIDE; BCR ABL PROTEIN; GAG PROTEIN; GELDANAMYCIN; HERBIMYCIN A; IMATINIB; INOSITOL; INTERFERON; LONAFARNIB; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PD 173995; PD173995; PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

ABELSON MURINE LEUKEMIA ONCOVIRUS; CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DEREGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME MECHANISM; FUSION GENE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MULTIPOTENT STEM CELL; MUTAGENESIS; MYRISTYLATION; NONHUMAN; OLIGOMERIZATION; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOGENETICS; DRUG DESIGN; GENES, ABL; HISTORY, 20TH CENTURY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 2542441665     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.012703.104753     Document Type: Review

References (360)

1. Virchow R. 1845. Weisses Blut. Froriep's Neue Notizen aus dem Gebiet der Natur.-und Heilkunde. Weimer 36:151-55
2. Craigie D. 1845. Case of disease of the spleen, in which death took place in consequence of the presence of purulent matter in the blood. Edinb. Med. Surg. J. 64:400-13
3. Bennett J. 1845. Case of hypertrophy of the spleen liver, in which death took place from suppuration of the blood. Edinb. Med. Surg. J. 64:413-23
4. Nowell PC, Hungerford DA. 1960. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497
5. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355-65
6. Shepherd P, Suffolk R, Halsey J, Allan N. 1995. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br. J. Haematol. 89:546-54
7. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, et al. 1992. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 80:2983-90
8. Lichtman MA. 1995. Chronic myelogenous leukemia and related disorders. In Williams Hematology, ed. E Buetler, MA Lichtman, BS Coller, TJ Kipps, pp. 298-324. New York: McGraw-Hill
9. Colleoni GW, Yamamoto M, Kerbauy J, Serafim RC, Lindsey CJ, et al. 1996. BCR-ABL rearrangement in adult T-cell acute lymphoblastic leukemia. Am. J. Hematol. 53:277-78
10. Fabbiano F, Santoro A, Felice R, Catania P, Cannella S, Majolino I. 1998. bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia. Haematologica 83:856-57
11. Mitelman F. 1993. The cytogenetic scenario of chronic myeloid leukemia. Leuk. Lymphoma 11:11-15
12. Jennings BA, Mills KI. 1998. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk. Res. 22:899-903
13. Prokocimer M, Rotter V. 1994. Structure function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84:2391-411
14. Feinstein E, Cimino G, Gale RP, Alimena G, Bertheir R, et al. 1991. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA 88:6293-97
15. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. 1991. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 78:3259-68
16. Sill H, Goldman JM, Cross NCP. 1995. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013-16
17. Fialkow PJ, Jacobson RJ, Papayannopoulou T. 1977. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, and platelet monocyte/macrophage. Am. J. Med. 63:125-30
18. Fialkow PJ, Garder SM, Yoshida A. 1967. Clonal origin of chronic myelocytic leukemia in man. Proc. Natl. Acad. Arts Sci. 58:1468-71
19. Kabarowski JHS, Witte ON. 2000. Consequences of BCR-ABL expression within the haematopoietic stem cell in chronic myeloid leukemia. Stem Cells 18:399-408
20. Takahashi N, Miura I, Saitoh K, Miura AB. 1998. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92:4758-63
21. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. 2001. Chronic myelogenous leukemia. Hematology 2001:87-112
22. Moloney JB. 1962. The murine leukemias. Fed. Proc. Fed. Am. Soc. Exp. Biol. 21:19-31
23. Abelson HT, Rabstein LS. 1970. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 30: 2213-22
24. Rosenberg N, Witte ON. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 39:39-81
25. Rabstein LS, Gazdar AF, Chopra HC, Abelson HT. 1971. Early morphological changes associated with infection by a murine nonthymic lymphatic tumor virus. J. Natl. Cancer Inst. 46:481-91
26. Siegler R, Zajdel S. 1972. Pathogenesis of Abelson-virus-induced murine leukemia. J. Natl. Cancer Inst. 48:189-218
27. Scher CD, Siegler R. 1975. Direct transformation of 3T3 cells by Abelson murine leukemia virus. Nature 253:729-31
28. Rosenberg N, Baltimore D, Scher CD. 1975. In vitro transformation of lymphoid cells by Abelson murine leukemia virus. Proc. Natl. Acad. Sci. USA 72:1932-36
29. Goff SP, Gilboa E, Witte ON, Baltimore O. 1980. Structure of the Abelson murine leukemia virus and the homologous cellular gene: studies with cloned viral DNA. Cell 22:777-85
30. Reynolds FH, Sacks TL, Deobagkar DN, Stephenson JR. 1978. Cells non-productively transformed by Abelson murine leukemia virus express a high molecular weight polyprotein containing structural and non-structural components. Proc. Natl. Acad. Sci. USA 75:3974-78
31. Van de Yen WJM, Reynolds FH, Nalewaik RP, Stephenson JR. 1979. The nonstructural component of the Abelson murine leukemia virus polyprotein P120 is encoded by a newly acquired genetic sequences. J. Virol. 32:1041-45
32. Witte ON, Rosenberg N, Paskind M, Shields A, Baltimore D. 1978. Identification of an Abelson murine leukemia virus encoded protein present in transformed fibroblast and lymphoid cells. Proc. Natl. Acad. Sci. USA 75:2488-92
33. Witte ON, Rosenberg N, Baltimore D. 1979. Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface. J. Virol. 31:776-84
34. Witte ON, Ponticelli A, Gifford A, Baltimore D, Rosenberg N, Elder J. 1981. Phosphorylation of the Ableson murine leukemia virus transforming protein. J. Virol. 39:870-78
35. Ponticelli AS, Whitlock CA, Rosenberg N, Witte ON. 1982. In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog. Cell 29:953-60
36. Witte ON, Rosenberg NE, Baltimore D. 1979. Identification of a normal cellular protein cross-reactive to the major Abelson murine leukaemia virus gene product. Nature 281:396-98
37. Collett MS, Erikson RL. 1978. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA 75:2021-24
38. Witte ON, Sun L, Rosenberg N, Baltimore D. 1979. A trans-acting kinase identified cells transformed by Abelson MuLV cells. Cold Spring Harbor Symp. Quant. biol. 44:855-57
39. Van de Ven WJM, Reynolds FH Jr, Stephenson JR. 1980: The nonstructural components of polyproteins encoded by replication-defective mammalian transforming retroviruses are phosphorylated and have associated protein kinase activity. Virology 101:185-97
40. Witte ON, Goff S, Rosenberg N, Baltimore D. 1980. A transformation- defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc. Natl. Acad. Sci. USA 8:4993-97
41. Krebs EG, Beavo JA. 1979. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48:923-59
42. Witte ON, Dasgupta A, Baltimore D. 1980. Abelson murine leukaemia virus protein is phophorylated in vitro to form phosphotyrosine. Nature 283:826-31
43. Ambros V, Baltimore D. 1978. Protein is linked to the 5′ end of poliovirus RNA by a phosphodiester linkage to tyrosine. J. Biol. Chem. 253:5263-6 6
44. Kirkegaard K, Wang JC. 1978. Escherichia coli DNA topoisomerase I catalyzed linking of single-stranded rings of complementary base sequences. Nucleic Acids Res. 5:3811-20
45. Hunter T, Sefton BM. 1980. The transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA 77:1311-15
46. Konopka JE, Witte ON. 1985. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell. Biol. 5:3116-23
47. Rees-Jones RW, Goff SP. 1988. Insertional mutagenesis of the Abelson murine leukemia virus genome: Identification of mutants with altered kinase activity and defective transformation ability. J. Virol. 62:978-86
48. Engelman A, Rosenberg N. 1990. Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J. Virol. 64:4242-51
49. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogeneous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 243:290-93
50. Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, et al. 1982. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 299:747-49
51. Groffen J, Heisterkamp N, Stephenson JR, van Kessel AG, de Klein A, et al. 1983. c-sis is translocated from chromosome 22 to chromosome 9 in chronic myelocytic leukemia. J. Exp. Med. 158:9-15
52. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, van Kessel AG, et al. 1983. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-80
53. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, et al. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765-67
54. Canaani E, Steiner-Saltz D, Aghai E, Gale RP, Berrebi A, Januszewicz E. 1984. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet 1: 593-95
55. Konopka JB, Watanabe SM, Witte ON. 1984. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-42
56. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D. 1986. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212-14
57. 1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc. Natl. Acad. Sci. USA 82:1810-14
58. Davis RL, Konopka JB, Witte ON. 1985. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol. Cell. Biol. 5:204-13
59. Konopka JB, Davis RL, Watanabe SM, Ponticelli AS, Schiff-Maker L, et al. 1984. Only site-directed antibodies reactive with the highly conserved scrhomologous region of the v-abl protein neutralize kinase activity. J. Virol. 51:223-32
60. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. 1993. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor-independence. Mol. Cell. Biol. 13:1728-36
61. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. 1984. Philadelphia chromosomal break-points are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99
62. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. 1985. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-61
63. +c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 83:9768-72
64. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. 1985. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550-54
65. Grosveld G, Verwoerd T, van Agthoven T, de Klein A, Ramachandran KL, et al. 1986. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol. Cell. Biol. 6:607-16
66. Stam K, Heisterkamp N, Reynolds FH Jr, Groffen J. 1987. Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol. Cell. Biol. 7:1955-60
67. Melo JV. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375-84
68. Clark SC, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, et al. 1988. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239:775-77
69. Hermans A, Heisterkamp N, von Lindern M, van Baal S, Meijer D, et al. 1987. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51:33-40
70. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, et al. 1987. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 325:631-35
71. Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, et al. 1987. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325:635-37
72. Denny CT, Shah N, Ogden S, Willman C, McConnell T, et al. 1989. Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome positive acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 86:4254-58
73. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. 1987. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:85-88
74. Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, et al. 1987. A new fused transcript in Philadephia chromosome positive acute lymphocytic leukaemia. Nature 330:386-88
75. Walker LC, Ganesan TS, Dhut S, Gibbsons B, Lister TA, et al. 1987. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 329:851-53
76. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, et al. 1983. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306:239-42
77. Deininger MW, Goldman JM, Melo JV. 2000. The molecular biology of chronic myeloid leukemia. Blood 96:3343-56
78. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, et al. 1991. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 78:2411-18
79. Martial P, Mecucci C, Nizet Y, Stul M, Phillippe M, et al. 1990. P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma. Leukemia 4:751-54
80. Melo JV, Myint H, Gallon DA, Goldman JM. 1994. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8:208-11
81. Kurzrock R, Shlalrid M, Talpaz M, Kloetzer WS, Gutterman JU. 1987. Expression of c-abl in Philadelphia-positive acule myelogenous leukemia. Blood 70:1584-88
82. Mitani K, Sato Y, Tojo A, Ishikawa F, Kobayashi Y, et al. 1990. Philadelphia chromosome positive B-cell type malignanl lymphoma expressing an aberrant 190 kDa bcr-abl protein. Br. J. Haematol. 76:221-25
83. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, et al. 1996. Neutrophilic-Chronic Myeloid Leukemia: A dislinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410-14
84. Wilson G, Frost L, Goodeve A, Vandenberghe E, Peake I, Reilly J. 1997. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia. Blood 88:2410-14
85. Haferlach T, Winkemann M, Ramm-Petersen L, Meeder M, Schoch R, et al. 1997. New insights into the biology of Philadelphia-chromosome-posilive acute lymphoblastic leukaemia using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br. J. Haematol. 99:452-59
86. Kasprzyk A, Harrison CJ, Seeker-Walker LM. 1999. Investigation of clonal involvement of myeloid cells in Philadelphia-positive and high hyperdiploid acute lymphoblastic leukemia. Leukemia 13: 2000-6
87. Biernaux C, Sels A, Huez G, Stryckmans P. 1996. Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant. (Suppl.) 3:S45-47
88. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. 1998. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362-67
89. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. 1999. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:2675-81
90. Pinilla-Ibarz J, Cathcart K, Scheinberg DA. 2000. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev. 14:111-20
91. Melo JV, Gordon DE, Cross NCP, Goldman JM. 1993. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158-65
92. Lazaridou A, Chase A, Melo J, Garicochea B, Diamond J, Goldman J. 1994. Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia. Leukemia 8:454-57
93. 1. Cancer Res. 55:34-38
94. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, et al. 1996. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol. Cell. Biol. 16:4107-16
95. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, et al. 2001. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 30:274-82
96. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, et al. 1997. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20:299-304
97. Daley GQ, Van Etten RA, Jackson PK, Bernards A, Baltimore D. 1992. Non-myristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol. Cell Biochem. 12:1864-71
98. Daley GQ, McLaughlin J, Witte ON, Baltimore D. 1987. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH-3T3 fibroblasts. Science 237:532-37
99. Jackson P, Baltimore D. 1989. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:449-56
100. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, et al. 2003. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112:845-57
101. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, et al. 2003. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859-71
102. Barila D, Superti-Furga G. 1998. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18:280-82
103. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. 2003. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell. Biol. 23:3884-96
104. Harrison SC. 2003. Variation on an Src-like theme. Cell 112:737-40
105. McWhirter JR, Galasso DL, Wang JYJ. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13:7587-95
106. McWhirter JR, Wang JYJ. 1991. Activation of tyrosine kinase and microfilament-binding functions of c-abl by Ibcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11:1553-65
107. Muller AJ, Young JC, Pendergast A-M, Pondel M, Landau NR, et al. 1991. BCR first exon sequences specifically activate Bcr/Abl tyrosine kinase oncogene of Philadelphia chromosome positive human leukemias. Mol. Cell. Biol. 11:1785-92
108. McWhirter JR, Wang JY. 1997. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene 15:1625-34
109. Maru Y, Afar DE, Witte ON, Shibuya M. 1996. The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligermerization domain. J. Biol. Chem. 271:15353-57
110. Lugo TG, Pendergast A, Muller AJ, Witte ON. 1990. Tyrosine kinase activity transformation potency of bcr-abl oncogene products. Science 247:1079-82
111. Franz WM, Berger P, Wang JYJ. 1989. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8:137-47
112. Goga A, McLaughlin J, Pendergast AM, Parmar K, Muller A, et al. 1993. Oncogenic activation of c-ABL by mutation within its last exon. Mol. Cell. Biol. 13:4967-75
113. Maru Y, Witte ON, Shibuya M. 1996. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett. 379:244-46
114. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, et al. 2002. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99:2957-68
115. Brasher BB, Roumiantsev S, Van Etten RA. 2001. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene 20:7744-52
116. Dai Z, Pendergast AM. 1995. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:2569-82
117. Shi Y, Alin K, Goff SP. 1995. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-Abl transforming activity. Genes Dev. 9:2583-97
118. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, et al. 1998. Oncogenic abl and src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a ras-independent pathway. Genes Dev. 12:1415-24
119. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. 1991. BCR sequences essential for transformation by the BCR/ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161-71
120. Afar DEH, Goga A, McLaughlin J, Witte O, Sawyers CL. 1994. Differential complementation of BCR-ABL point mutants with c-MYC. Science 264:424-26
121. Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON. 1995. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981-88
122. Mayer BJ, Jackson PK, Van Etten RA, Baltimore D. 1992. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:609-18
123. McWhirter JR, Wang JYJ. 1993. An actin-binding function contributes to transformation by the bcr-abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMSO J. 12:1533-46
124. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, et al. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:764-73
125. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE. 1994. Coupling between p210bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J. Exp. Med. 179:167-75
126. Gishizky ML, Cortez D, Pendergast AM. 1995. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc. Natl. Acad. Sci. USA 92:10889-93
127. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. 2002. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479-92
128. Cortez D, Kadlec L, Pendergast AM. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of Apoptosis. Mol. Cell. Biol. 15:5531-41
129. dok: A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88:197-204
130. Yamanashi Y, Baltimore D. 1997. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 88:205-11
131. Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. 2001. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol. Cell. Biol. 21:840-53
132. Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS. 2002. BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99:4122-30
133. Skourides PA, Perera SA, Ren R. 1999. Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins. Oncogene 18:1165-76
134. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, et al. 1997. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 89: 297-306
135. Senechal K, Halpern J, Sawyers CL. 1996. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J. Biol. Chem. 271:23255-61
136. Maru YM, Witte ON. 1991. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 67:459-68
137. Liu JX, Wu Y, Ma GZ, Lu D, Haataja L, et al. 1996. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol. Cell. Biol. 16:998-1005
138. Liu JX, Wu Y, Arlinghaus RB. 1996. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res. 56:5120-24
139. Radziwill G, Erdmann RA, Margelisch U, Moelling K. 2003. The Bcr kinase down-regulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol. Cell. Biol. 23:4663-72
140. Cortez D, Reuther G, Pendergast AM. 1997. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15:2333-12
141. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, et al. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16:6151-61
142. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, et al. 1993. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 82:1838-17
143. Voss J, Posern G, Hannemann JR, Wiedemann LM, Turhan AG, et al. 2000. The leukaemic oncoproteins Bcr-Abl T and el-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene 19:1684-90
144. Sawyers CL, McLaughlin J, Witte ON. 1995. Genetic requirement for ras in the transformation of fibroblasts hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181:307-13
145. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, et al. 2001. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-12
146. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. 1991. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol. Cell. Biol. 11:1107-13
147. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. 2000. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol. 20:1179-86
148. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. 2001. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20:5826-35
149. Gaston I, Stenberg PE, Bhat A, Druker BJ. 2000. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells. Exp. Hematol. 28:77-86
150. Witt O, Sand K, Pekrun A. 2000. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95:2391-96
151. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. 1995. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92:11746-50
152. Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. 2002. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21:5868-76
153. + cells with aBCR/ABL-containing retroviral vector. Blood 97:2406-12
154. + cells. Blood 92:2461-70
155. Gishizky ML, Witte ON. 1992. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836-39
156. Pierce A, Spooncer E, Wooley S, Dive C, Francis JM, et al. 2000. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene 19:5487-97
157. Perlingeiro RC, Kyba M, Daley GQ. 2001. Clonal analysis of differentiating embryonic stem cells reveals a hematopoietic progenitor with primitive erythroid and adult lymphoid-myeloid potential. Development 128:4597-604
158. Era T, Witte ON. 2000. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl. Acad. Arts Sci. 97:1737-42
159. Wong S, McLaughlin J, Cheng D, Witte O. 2003. Cell context specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 101:4088-97
160. Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, et al. 2001. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 20:8249-57
161. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, et al. 1989. A bcr-v-abl oncogene induces lymphomas in trans-genic mice. Mol. Cell. Biol. 9:2798-805
162. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature 344:251-53
163. Wong S, Witte ON. 2001. Modeling Philadelphia chromosome positive leukemias. Oncogene 20:5644-59
164. Clark SS, Chen E, Fizzotti M, Witte ON, Malkovska V. 1993. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J. Virol. 67:6033-46
165. Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemiain mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824-30
166. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. 1990. Induction of achronic myelogenous leukemia-like syndrome in mice with v-abl BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649-53
167. Gishizky ML, Johnson-White J, Witte ON. 1993. Efficient transplantation of BCR/ABL induced chronic myelogenous leukemia-like syndrome in mice. Proc. Natl. Acad. Sci. USA 90:3755-59
168. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. 1991. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol. Cell. Biol. 11:4710-16
169. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-92
170. Zhang X, Ren R. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829-40
171. Henkemeyer M, West SR, Gertier FB, Hoffmann FM. 1990. A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localization. Cell 63:949-60
172. Heisterkamp N, Voncken JW, Senadheera D, Hemmeryckx B, Gonzalez-Gomez I, et al. 2001. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice. Int. J. Mol. Med. 7:351-57
173. Zhang X, Wong R, Hao SX, Pear WS, Ren R. 2001. The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency phenotype. Blood 97:277-87
174. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. 2001. The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4-13
175. Million RP, Van Etten RA. 2000. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96:664-70
176. Ren R. 2002. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21:8629-42
177. Reichert A, Heisterkamp N, Daley GQ, Groffen J. 2001. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor. Blood 91:1399-403
178. Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ. 2001. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Oncogene 20:2636-46
179. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. 1996. Constitutive activation of STATS by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-54
180. Ilaria RL Jr, Van Etten RA. 1996. P210 P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704-10
181. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, et al. 2000. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- bcr/abl-induced transformation are independent of stat5. Blood 96:2277-83
182. Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, et al. 2001. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J. Exp. Med. 194:275-84
183. Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. 2001. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chrome myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97:1442-50
184. Huettner CS, Zhang P, Van Etten RA, Tenen DG. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:57-60
185. Kabarowski JHS, Allen PB, Wiedemann L. 1994. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 13:5887-95
186. Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, et al. 1990. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Nad. Acad. Arts Sci. 87:3743-77
187. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, et al. 1996. Immunodeficiency chronic and myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-17
188. Hao SX, Ren R. 2000. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliterative disorder. Mol. Cell. Biol. 20:1149-61
189. Eklund EA, Jalava A, Kakar R. 1998. PU.1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91(phox) expression. J. Biol. Chem. 273:13957-65
190. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. 1993. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol. 13:841-51
191. Mollinedo F, Vaquerizo MJ, Naranjo JR. 1991. Expression of c-jun, jun B and jun D proto-oncogenes in human peripheral-blood granulocytes. Biochem. J. 273:477-79
192. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. 2001. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell 104:21-32
193. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. 2000. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 19:2056-68
194. Passegue E, Wagner EF. 2000. JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 19:2969-79
195. Afar DEH, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. 1995. Signaling by ABL oncogenes through cyclin D1. Proc. Natl. Acad. Sci. USA 92:9540-44
196. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. 2003. Expression of BCR-ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc. Natl. Acad. Sci. USA 100(17):10002-7
197. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, et al. 1999. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1610-20
198. Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, et al. 1999. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell. Biol. 19: 7473-80
199. Gishizky ML, Witte ON. 1992. BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. Curr. Top. Microbiol. Immunol. 182:65-72
200. Sawyers CL. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340:1330-40
201. Druker BJ, O'Brien SG, Cortes J, Radich J. 2002. Chronic myelogenous leukemia. Hematology 2002:111-35
202. Salesse S, Verfaillie CM. 2002. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 21:8547-59
203. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha-A in chronic myelogenous leukemia. W. Engl. J. Med. 314:1065-69
204. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, et al. 2003. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-41
205. Darnell JE Jr, Kerr M, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-21
206. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, et al. 2000. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol. J. 1:7-14
207. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. 2002. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100:2926-31
208. Starr R, Willson TA, Viney EM, Murray LJL, Rayner JR, et al. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-21
209. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-24
210. Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, et al. 1998. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 92:1668-76
211. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, et al. 1998. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91:22-29
212. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang WD, et al. 2003. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111:639-417
213. Deng M, Daley GQ. 2001. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97: 3491-97
214. Levitzki A, Gazit A. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-88
215. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-34
216. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. 2001. The sequence of the human genome. Science 291:1304-51
217. Uehara Y, Hori M, Takeuchi T, Umezawa H. 1985. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn. J. Cancer Res. 76:672-75
218. Uehara Y, Murakami Y, Mizuno S, Kawai S. 1988. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164:294-98
219. Taniguchi M, Uehara Y, Matsuyama M, Takahashi M. 1993. Inhibition of ret tyrosine kinase activity by herbimycin A. Biochem. Biophys. Res. Commun. 195:208-14
220. Fukazawa H, Li PM, Yamamoto C, Murakami Y, Mizuno S, Uehara Y. 1991. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem. Pharmacol. 42:1661-71
221. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N. 1995. Herbimycin A induces the 20 S proteasome- ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. 270:16580-87
222. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:5592-95
223. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, et al. 1986. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. 39:170-73
224. Umezawa K, Hori T, Tajima H, Imoto M, Isshiki K, Takeuchi T. 1990. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 260:198-200
225. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, et al. 1996. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 88:3091-100
226. Kawada M, Tawara J, Tsuji T, Honma Y, Hozumi M. 1993. Inhibition of Abelson oncogene function by erbstatin analogues. Drugs Exp. Clin. Res. 19:235-41
227. Yaish P, Gazit A, Gilon C, Levitzki A. 1988. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933-35
228. Levitzki A. 2002. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer 38(Suppl. 5):S11-18
229. bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82:3524-29
230. + chronic myelogenous leukemia progenitor cells. Blood 93:3973-82
231. Bhatia R, Munthe HA, Verfaillie CM. 1998. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores betal integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 12:1708-17
232. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, et al. 2002. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99:664-71
233. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-48
234. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, et al. 2001. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21:499-512
235. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, et al. 2002. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38(Suppl. 5):S19-27
236. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. 1995. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Arts Sci. 92:2558-62
237. Hubbard SR, Till JH. 2000. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:373-98
238. Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB. 1992. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. 52:4492-98
239. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, et al. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-52
240. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:139-45
241. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96:925-32
242. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, et al. 1996. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:100-4
243. Okuda K, Weisberg E, Gilliland DG, Griffin JD. 2001. ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-48
244. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-66
245. Deininger MW, Goldman JM, Lydon N, Melo JV. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-98
246. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:380-94
247. Buchdunger E, O'Reilly T, Wood J. 2002. Pharmacology of imatinib (STI571). Eur. J. Cancer 38(Suppl. 5):S28-36
248. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
249. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:645-52
250. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-42
251. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, et al. 2002. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-37
252. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-39
253. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, et al. 2003. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473-75
254. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-80
255. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette EL, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-25
256. le Courre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, et al. 2000. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758-66
257. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. 2000. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070-79
258. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, et al. 2003. Detection of BCR-ABL mutations in imatinib-treated CML patients is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-83
259. Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW. 2003. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-14
260. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, et al. 2003. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368-73
261. Di Bacco A, Keeshan K, McKenna SL, Cotter TG. 2000. Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth apoptosis. Oncologist 5:405-15
262. Donate NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. 2003. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-98
263. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kurlyan J. 2000. Structural mechanism of STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-42
264. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 imatinib (STI-571). Cancer Res. 62:4236-43
265. Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112:831-43
266. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-96
267. Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, et al. 1999. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 18:2676-80
268. Salloukh HF, Laneuville P. 2000. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 14:1401-4
269. Brain J, Saksena A, Laneuville P. 2002. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leuk. Res. 26:1011-16
270. Kreuzer KA, Le Courre P, Landt O, Na IK, Schwarz M, et al. 2003. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. 82:284-89
271. Takeda N, Shibuya M, Maru Y. 1999. The BCR-ABL oncoprotein potentially interacts with the xeroderaia pigmentosum group B protein. Proc. Natl. Acad. Sci. USA 96:203-7
272. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, et al. 1998. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 58:3237-42
273. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, et al. 2003. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101:4583-88
274. Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, et al. 2001. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97:2084-90
275. Spangrude GJ, Heimfeld S, Weissman IL. 1988. Purification and characterization of mouse hematopoietic cells. Science 241:58-62
276. Negrin RS, Weissman I. 1992. Hematopoietic stem cells in normal and malignant states. Marrow Transpl. Rev. 2:23-26
277. Holyoake T, Jiang X, Eaves C, Eaves A. 1999. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-64
278. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, et al. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-25
279. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, et al. 2003. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701-7
280. Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. 2003. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101:5010-13
281. Petzer AL, Gunsilius E, Hayes M, Stock-hammer G, Duba HC, et al. 2002. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br. J. Haematol. 117:623-25
282. Le LQ, Kabarowski JH, Wong S, Nguyen K, Gambhir SS, Witte ON. 2002. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell 1:381-91
283. Phelps ME. 2000. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. USA 97: 9226-33
284. Iyer M, Barrio JR, Namavari M, Bauer E, Satyamurthy N, et al. 2001. 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J. Nucl. Med. 42:96-105
285. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, et al. 2002. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62:4244-55
286. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, et al. 2002. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21:8804-16
287. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. 2003. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res. 9:1267-73
288. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. 2002. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:7149-53
289. Blencke S, Ullrich A, Daub H. 2003. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278:15435-40
290. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, et al. 2003. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63:375-81
291. Wilda M, Fuchs U, Wossmann W, Borkhardt A. 2002. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21:5716-24
292. Rapozzi V, Burm BE, Cogoi S, van der Marel GA, van Boom JH, et al. 2002. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res. 30:3712-21
293. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, et al. 1991. Selective inhibition of luekemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562-65
294. Lange W, Cantin EM, Finke J, Dolken G. 1993. In vitro in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786-94
295. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P. 1993. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp. Hematol. 21:1714-18
296. Perkins C, Kim CN, Fang G, Bhalla KN. 2000. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95:1014-22
297. Nimmanapalli R, O'Bryan E, Bhalla K. 2001. Geldanamycin and its analogue 17-ally lamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61:1799-804
298. An WG, Schulte TW, Neckers LM. 2000. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11:355-60
299. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, et al. 2001. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15:1537-43
300. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. 2002. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100:3041-44
301. Wang Y, Liu J, Wu Y, Luo W, Lin S-H, et al. 2001. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth induces cell death. Cancer Res. 61:138-44
302. Lim Y-M, Wong S, Lau G, Witte ON, Colicelli J. 2000. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc. Natl. Acad. Sci. USA 97:12233-38
303. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, et al. 2001. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 98:1773-81
304. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, et al. 2003. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia other hematologic malignancies. Blood 101:1692-97
305. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, et al. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-10
306. Demetri GD. 2002. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur. J. Cancer 38(Suppl. 5):S52-59
307. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, et al. 2003. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22:660-64
308. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. 2002. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. 1:1115-24
309. Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, et al. 2003. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br. J. Haematol. 120:251-56
310. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:1201-14
311. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the plateletderived growth factor receptor beta. N. Engl. J. Med. 347:481-87
312. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. 2003. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3:173-83
313. Sawyers CL. 2002. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1:413-15
314. Gilliland DG, Tallman MS. 2002. Focus on acute leukemias. Cancer Cell 1:417-20
315. Thaker HK, Snow MH. 2003. HIV viral suppression in the era of antiretroviral therapy. Postgrad. Med. J. 79:36-42
316. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, et al. 2002. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA 99:16220-25
317. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. 1998. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:968-81
318. Hamdane M, David-Cordonnier MH, D'Halluin JC. 1997. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 15: 2267-75
319. Gross AW, Zhang X, Ren R. 1999. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol. Cell Biochem. 19:6918-28
320. Anderson SM, Mladenovic J. 1996. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood 87:238-44
321. + cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc. Natl. Acad. Arts Sci. 97:10538-43
322. Parada Y, Banerji L, Glassford J, Lea NC, Collado M, et al. 2001. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J. Biol. Chem. 276:23572-80
323. Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, et al. 2002. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 196:667-78
324. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. 1999. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc. Natl. Acad. Arts Sci. 96:12804-9
325. Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, et al. 1999. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93:2707-20
326. Odai H, Sasaki K, Iwamatsu A, Nakamoto T, Ueno H, et al. 1997. Purification molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phophatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, eiythropoietin, and Bcr-Abl. Blood 89:2745-56
327. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. 1994. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269:22925-28
328. + leukemia. Blood 84:1731-36
329. Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, et al. 2001. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 61:8005-13
330. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. 1996. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res. 56:3426-30
331. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, et al. 1995. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J. Biol. Chem. 270:29145-50
332. +BCR/ABL. J. Biol. Chem. 270:5039-47
333. Coutinho S, Jahn T, Lewitzky M, Feller S, Hutzler P, et al. 2000. Characterization of Grb4, an adapter protein interacting with Bcr-Abl. Blood 96:618-24
334. Weng Z, Fluckiger AC, Nisitani S, Wahl MI, Le LQ, et al. 1998. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc. Natl. Acad. Arts Sci. 95:12334-39
335. Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS, Boswell HS. 1995. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 9:1499-507
336. Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. 2001. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 15:1424-32
337. Andoniou CE, Thien CBF, Langdon WY. 1996. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Oncogene 12:1981-89
338. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. 1995. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J. Biol. Chem. 270:21468-71
339. bcr/abl in myeloid cells. Cancer Res. 56:3589-96
340. Afar DEH, Han L, McLaughlin J, Wong S, Dhaka A, et al. 1997. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6:773-82
341. LaMontagne KR Jr, Flint AJ Jr, Franza BR, Pendergast AM, Tonksl NK. 1998. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol. Cell. Biol. 18:2965-75
342. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, et al. 2002. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 21:5766-74
343. Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, et al. 1998. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Arts Sci. 95:11858-62
344. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. 2002. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767-75
345. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, et al. 2001. BCR/ABL regulates mammalian recA homologs, resulting in drug resistance. Mol. Cell 8:795-806
346. Ernst TJ, Slattery KE, Griffin JD. 1994. p210Bcr/Abl p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J. Biol. Chem. 269:5764-69
347. Maru Y, Peters KL, Afar DE, Shibuya M, Witte ON, Smithgall TE. 1995. Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS. Mol. Cell. Biol. 15:835-42
348. Vieira SA, Deininger MW, Sorour A, Sinclair P, Foroni L, et al. 2001. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer 32:353-63
349. Shi CS, Tuscano JM, Witte ON, Kehrl JH. 1999. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood 93:1338-45
350. Schuster C, Forster K, Dierks H, Elsasser A, Behre G, et al. 2003. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood 101:655-63
351. Heriche JK, Chambaz EM. 1998. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 17:13-18
352. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. 1998. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16:1383-90
353. Jamieson L, Carpenter L, Biden TJ, Fields AP. 1999. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J. Biol. Chem. 274:3927-30
354. Sanchez-Garcia I, Grutz G. 1995. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Arts Sci. 92:5287-91
355. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. 1998. BCR-ABL activates pathways mediating cytokine independence protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene 16:335-48
356. Xie SH, Wang Y, Liu JX, Sun T, Wilson MB, et al. 2001. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20:6188-95
357. Salomoni P, Condorelli F, Sweeney SM, Calabretta B. 2000. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 96:676-84
358. BCR/ABL. EMBO J 14:257-65
359. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. 2003. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. USA 100:6523-28
360. Trotta R, Vignudelli T, Candini O, Inline RV, Pecorari L, et al. 2003. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 3:145-60